

Neon Therapeutics Logo

Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference

June 3, 2019

CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O'Dowd, Chief Executive Officer of Neon, will present at the Jefferies 2019 Healthcare Conference on Friday, June 7, 2019 at 12:30 p.m. ET.

A live webcast of the presentation will be available by visiting the Investors section of Neon Therapeutics' website at ir.neontherapeutics.com. A replay of the webcast will be archived on the Neon Therapeutics website for 30 days following the presentation.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical-stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of hormone receptor-positive (HR+) breast cancer.

For more information, please visit www.neontherapeutics.com.

Investor Contact:

Paul Cox, Corporate Affairs and Strategy

pcox@neontherapeutics.com

617-337-4762

Media Contact:

Stephanie Simon, Ten Bridge Communications

stephanie@tenbridgecommunications.com

617-581-9333



Source: Neon Therapeutics, Inc.